Arctic Bioscience AS stock analysis
Arctic Bioscience AS (9TD) Stock Price & Analysis
9TD Stock Chart & Stats
- Day’s Range
- EUR 0.18 - EUR 0.22
- 52-Week Range
- EUR 0.08 - EUR 0.36
- Previous Close
- EUR 0.17
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 6.85M
- Enterprise Value
- EUR 167.56M
- Total Cash (Recent Filing)
- EUR 2.16M
- Total Debt (Recent Filing)
- EUR 32.86M
- Price to Earnings (P/E)
- ―
- Beta
- -0.73
- Next Earnings
- May 13, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Arctic Bioscience AS News
Arctic Bioscience Posts New Psoriasis Inflammation Data Backing Herring Roe Oil Drug
Arctic Bioscience AS ( ($DE:9TD) ) has issued an announcement. Arctic Bioscience has reported new peer-reviewed data showing that herring roe oil led to significant reductions in blood-based inflammatory biomarkers
Arctic Bioscience Publishes 2025 Annual Report After Board Approval
Arctic Bioscience AS ( ($DE:9TD) ) just unveiled an update. Arctic Bioscience, a biotechnology company specialising in marine-based pharmaceuticals and dietary supplements, is developing the oral psoriasis drug candidate HRO350
9TD FAQ
What was Arctic Bioscience AS’s price range in the past 12 months?
What is Arctic Bioscience AS’s market cap?
When is Arctic Bioscience AS’s upcoming earnings report date?
How were Arctic Bioscience AS’s earnings last quarter?
Is Arctic Bioscience AS overvalued?
Does Arctic Bioscience AS pay dividends?
What is Arctic Bioscience AS’s EPS estimate?
How many shares outstanding does Arctic Bioscience AS have?
What happened to Arctic Bioscience AS’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Arctic Bioscience AS?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Arctic Bioscience AS
Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis. It also sells nutraceuticals as intermediary and finished goods products under the ROMEGA brand name. Arctic Bioscience AS was incorporated in 2011 and is headquartered in Ørsta, Norway.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Christer Ludvig Valderhaug
- Employees
- 19
- Website
- www.arctic-bioscience.com
- Address
- Industrivegen 42, Ørsta, MR, 6155, NO
Arctic Bioscience AS (9TD) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 4 | 6 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 8 | 0 | 4 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| DE:ALBAllgaeuer Brauhaus AG |




